Premium
Liraglutide‐induced acute kidney injury
Author(s) -
Narayana S Koppa,
Talab SK,
Elrishi MA
Publication year - 2012
Publication title -
practical diabetes
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.205
H-Index - 24
eISSN - 2047-2900
pISSN - 2047-2897
DOI - 10.1002/pdi.1727
Subject(s) - liraglutide , medicine , nausea , type 2 diabetes , incretin , diabetes mellitus , vomiting , glucose homeostasis , insulin resistance , exenatide , endocrinology , gastroenterology
Type 2 diabetes is a progressive disease characterised by insulin resistance and pancreatic beta‐cell dysfunction. It eventually leads to insulin deficiency and hyperglycaemia. Glucagon‐like peptide‐1 (GLP‐1) is an incretin hormone playing a role in glucose homeostasis which is rapidly degraded and eliminated, because of a short half‐life. Liraglutide is an acylated GLP‐1 analogue with a prolonged half‐life. It has a plasma half‐life of 13 hours after subcutaneous administration. The side effects reported with liraglutide are gastrointestinal: mainly nausea, vomiting, diarrhoea, abdominal pain and heartburn. These effects are more frequent when starting on treatment and usually stop with persistent treatment with liraglutide. We present two type 2 diabetes patients who developed renal impairment after liraglutide therapy that reversed to normal after stopping the drug and adequate hydration. Copyright © 2012 John Wiley & Sons.